cme e-mini sp 500 |
||||||
|
News for 29-Jun-26 Source: MedicineNet Prevention and Wellness General Source: MedicineNet Senior Health General Source: MedicineNet Senior Health General Source: MedicineNet Prevention and Wellness General
|
The Best cme e-mini sp 500 websiteAll the cme e-mini sp 500 information you need to know about is right
here. Presented and researched by http://www.md-news.net. We've searched
the information super highway far and wide to provide you with the
best cme e-mini sp 500 site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
cme e-mini sp 500
Knowing you're getting value for money is very important in buying cme e-mini sp 500, so by coming to this web site you can rest with the sound knowledge that you are getting the cme e-mini sp 500 you paid for. By buying through our recommend links you can also rest assured your cme e-mini sp 500 will be of the highest quality. How do we know? Because when we're shopping for cme e-mini sp 500 ourselves it's where we go. You might wonder why we're suggesting you click on some outside links rather than stay on our cme e-mini sp 500 site. Well it's because we've only just put this site up and haven't yet got it fully operational. Our aim is to be the best site for cme e-mini sp 500 info on the net, and I'm sure that one day soon we'll achieve it. So please bookmark us and come back soon. Meanwhile please follow one of the links. cme e-mini sp 500
The Internet abounds with all sorts of information on cme e-mini sp 500, but unless you can be reasonably sure of its source and accuracy, be wary. For example, information about cme e-mini sp 500 posted in Internet newsgroups can be flawed. Even if the cme e-mini sp 500 document contains great technical detail, there is often no hard evidence to back up the claims. Don't make the mistake of accepting gossip as truth, which may prove to be professionally and financially embarrassing. While embarrassment is rarely fatal, more serious consequences can result from following cme e-mini sp 500 advice posted in newsgroups or on websites. While someone may be well-meaning in offering the information, can you trust it? Is this person a cme e-mini sp 500 consumer who has actually purchased and used the products or are they just an opinionated individual? Or are they a competitor? Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||||
|
http://www.medmeet.com/ |
||||||
| Medical Meetings Medical Newscast Medical Meetings On The Net |